(Total Views: 176)
Posted On: 06/03/2019 8:00:43 AM
Post# of 21237

$HTBX News Article - Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure https://marketwirenews.com/news-releases/heat...87598.html


My Twitter: WhyteStocks